| Document |
Document Title |
|
WO/2024/039740A2 |
Provided herein are compositions comprising non-standard amino acids containing glycan stubs to generate a population of polypeptides with homogeneous sugar moieties and methods of use thereof for the treatment of diseases and conditions.
|
|
WO/2024/040270A2 |
Bioinspired adhesives comprising a macromolecule such as zein and one or more catechol- or gallol-containing compounds are provided. The adhesive can also comprise an iron crosslinker, an interfacial crosslinker, or both an iron crosslin...
|
|
WO/2024/037743A1 |
Described herein are proteins comprising an ankyrin repeat domain with a mutation in the N-terminal capping module, in particular a mutation at position 17 of the N-terminal capping module, as well as related products and methods.
|
|
WO/2024/040030A2 |
This disclosure relates to methods of treating and diagnosing protein misfolding disorders. In some embodiments, the treatment is with gene therapy, gene editing, or administration of protective proteins.
|
|
WO/2024/040125A1 |
This disclosure provides crystalline forms of a compound of Formula (I), as well as pharmaceutically acceptable compositions thereof, and methods for their preparation and use in methods of treating hypercholesterolemia and other conditi...
|
|
WO/2024/040132A2 |
This disclosure provides compositions and methods comprising combinations of IL-15 or an I L-15/IL-15Ra complex with one or more other active agents for the treatment of cancer. This disclosure also provides compositions and methods comp...
|
|
WO/2024/040245A1 |
The present disclosure relates to peptide having a sequence comprising: X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19X20X21X22X23
X24X25X26X27X28NH2 (SEQ ID NO: 1), And to their isomers, pharmaceutically acceptable salts, or prodrugs ...
|
|
WO/2024/038067A1 |
A combination therapy is provided, which comprises - Compound I (GLP-1R/glucagon receptor dual agonist): H-His-Ac4c-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-A
sp-Glu-Arg-Ala-Ala-Lys-Asp-Phe-Ile-Lys(HOOC-(CH2)16-CO-γGlu
-Gly-Ser-G...
|
|
WO/2024/038112A1 |
Via yeast display technology, albumin binding variants were selected, and variants displayed improved binding to MSA or both HSA & MSA. All variants were subcloned into the pHEN-expression plasmid and expressed in E coli WK6 cells. Purif...
|
|
WO/2024/036839A1 |
Provided are a gene-modified cell drug expressing phenylalanine hydroxylase (PAH), a method for preparing same, and use thereof. The gene-modified cell drug expressing PAH comprises a cell modified by the human normal phenylalanine hydro...
|
|
WO/2024/035377A2 |
|
|
WO/2024/034200A1 |
Disclosed are a highly rigid peptide linker inserted between a transmembrane protein and an organelle transport signal, a fusion protein containing the same, and a localization method that includes inserting a peptide linker.
|
|
WO/2024/036144A1 |
The present disclosure relates, inter alia, to methods for the prevention and/or reduction of immune checkpoint inhibitor-mediated gastrointestinal side effects by administering therapeutic intestinal alkaline phosphatases. The present d...
|
|
WO/2024/035137A1 |
The present invention relates to a Bacillus subtilis flagellin variant and a use thereof, and more specifically to a flagellin variant and a use thereof, the flagellin variant having improved storage stability and reduced immunogenicity ...
|
|
WO/2024/033329A2 |
The present disclosure relates to antagonists that target, directly or indirectly, Serine/Arginine Rich Splicing Factor 1 (SRSF1); viral vectors comprising a nucleic acid sequence encoding SRSF1 antagonists. The use of said vector in gen...
|
|
WO/2024/035023A1 |
The present invention provides: a Bax protein variant in which lysine at position 128, lysine at position 190, or lysines at positions 128 and 190 in a Bax protein is(are) substituted with arginine; a method for increasing the half-life ...
|
|
WO/2024/031131A1 |
The present disclosure relates generally to novel compositions and methods for delivery of truncated midkine proteins in which the amino acid sequence encoded by exon 4 of human midkine is absent or partially absent and/or polynucleotide...
|
|
WO/2024/033278A1 |
The invention relates to a novel process for manufacturing 4-[(11S,14S,17S)-14-(4-Aminobutyl)-11-(3-aminopropyl)-17-(1H
-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,
16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3(8),4...
|
|
WO/2024/036257A1 |
Provided herein are methods for treating drug addiction in a subject, the method comprising activating neurokinin B (NKB)-expressing neurons of the subject. Also provided herein are compositions useful for the treatment of drug addiction...
|
|
WO/2024/031188A1 |
There is provided a composition for modifying a T cell, the composition comprising: a protein complex comprising a polynucleotide-modifying enzyme domain, a T cell membrane binding domain and an endosome escape domain; a guide oligonucle...
|
|
WO/2024/035782A1 |
The invention described herein provides an engineered insulin polypeptide comprising two cleavable peptides interposed between the insulin B-chain and the C-peptide, and between the C-peptide and the insulin A-chain to secrete active ins...
|
|
WO/2024/032457A1 |
Disclosed in the present invention is a long-acting teriparatide compound. The long-acting compound of the present invention is used for preparing a pharmaceutical composition for treating diseases, and the pharmaceutical composition is ...
|
|
WO/2024/035884A1 |
Disclosed herein are kits and methods for treating pulmonary arterial hypertension (PAH), comprising administering to a subject in need thereof: • a therapeutically effective amount of a tyrosine kinase inhibitor or a pharmaceutically ...
|
|
WO/2024/035144A1 |
The present invention generally relates to an extracellular vesicle (EV) comprising a subunit of a heterodimeric transcription factor, an EV polypeptide, and a monomeric cis-cleaving intein and a method of using the EV.+
|
|
WO/2024/032485A1 |
The present invention relates to a non-phosphorylated and non-ubiquitinated CREPT protein and use thereof. Specifically, the present invention relates to a protein that is obtained by modifying CREPT or a homologous protein thereof. The ...
|
|
WO/2024/031163A1 |
The present invention describes opioid peptides that can be used to prepare antinociceptive medicines. Specifically, the present invention comprises three peptides with surprising antinociceptive efficacy and no detectable adverse effect...
|
|
WO/2024/031166A1 |
The present invention relates to an antiviral and intranasal formulation composed of surfactin and perillyl alcohol, capable of reaching the pulmonary alveoli for the treatment of infection caused by viruses. The present invention relate...
|
|
WO/2024/033530A1 |
The present invention relates to the human Interleukin 1 Receptor antagonist anakinra for use in the treatment of Post-Acute COVID Syndrome (PACS), wherein said treatment comprises administration of a dose of at least approximately 100 m...
|
|
WO/2024/031181A1 |
Breast cancer is now the most prevalent cancer worldwide, and despite therapeutical advances in the last decades, metastatic breast cancer remains an incurable disease. Novel tumor-specific antigens (TSAs) and tumor-associated antigens (...
|
|
WO/2024/032821A1 |
Provided is a new and highly toxic amyloid oligomer Aβo*3F. The Aβo*3F is specifically bound by a 3F antibody, is the most important toxic ingredient in a mixture of Aβ oligomers, and has a strong pathogenic effect. Further provided i...
|
|
WO/2024/032454A1 |
Disclosed in the present invention is a long-acting abaloparatide compound. The long-acting compound of the present invention is used for preparing a pharmaceutical composition for treating diseases. Provided is a use of the pharmaceutic...
|
|
WO/2024/036005A1 |
A method for treating Alzheimer's disease is disclosed. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). A composition for treating Alzheimer's disease is also disclosed.
|
|
WO/2024/033418A1 |
The present invention relates to a compound of formula (I), pharmaceutically acceptable salts thereof as well as pharmaceutical compositions comprising the same and, in particular, the compounds of formula (I) and pharmaceutical composit...
|
|
WO/2024/033917A1 |
Provided herein is a composition comprising solid particles or granules comprising Phosphorylcholine-tuftsin conjugate including a salt thereof, and ester end-capped poly(glycolide-co-lactide), wherein the Phosphorylcholine- tuftsin conj...
|
|
WO/2024/031963A1 |
Disclosed are a chimeric compound for degrading cyclophilin A, a preparation method therefor, and use thereof. The structural formula of the chimeric compound is represented by formula I. The compound represented by formula I provided by...
|
|
WO/2024/035929A2 |
This disclosure provides an isolated recombinant peptide comprising one or more of the FBP1 E1-E7 fragment or an equivalent thereof and a cell penetrating peptide, compositions and methods of using same to reverse insulin resistance in a...
|
|
WO/2024/032486A1 |
The present invention relates to a CREPT mutant and use thereof in the inhibition of tumor growth. In particular, the present invention relates to a protein obtained by replacing a residue at position 134 of SEQ ID NO: 4 with a residue t...
|
|
WO/2024/033929A1 |
An isolated peptide comprising an amino acid sequence of a lysyl oxidase (LOX) family member target site of an extracellular matrix protein, the peptide being no longer than 50 amino acids, for use in treating a disease associated with f...
|
|
WO/2024/036145A1 |
A method to prevent a disease, comprising: (1) administering a peptide comprising Delta6PV into a subject comprising a human or an animal; wherein the disease comprises one of more of Type 1 Diabetes, Rheumatoid arthritis, Lupus, Sjogren...
|
|
WO/2024/036226A1 |
Provided herein is a method for treating autism or autism spectrum disorders. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). Also provided is a composition for treating autis...
|
|
WO/2024/033928A1 |
Method of increasing collagen production and tissue regeneration or repair using an agent that increases an amount of Hypoxia- inducible factor- 1 (HIF-1) in the cells, the amount being selected to cause an increase in the amount of coll...
|
|
WO/2024/031297A1 |
Provided are a recombinant adenovirus or adenoviral vector expressing GLP1 receptor agonist that shows expected anti-tumor effects and prolonged survival time in tumor-bearing subjects and the pharmaceutical composition comprising the same.
|
|
WO/2024/036044A1 |
Provided herein are compositions and methods for treating or preventing metabolic disorders and cancer. In particular, provided herein are compositions, methods, and uses of inhibitors of phosphorylation of AMPKalpha1 at Serine496 and AM...
|
|
WO/2024/015605A9 |
The present disclosure relates to systems and methods for immune therapy. For example, a method can be used to enhance the proliferation of chimeric antigen receptor (CAR) T cells in a subject, The method comprises administering to the s...
|
|
WO/2024/031965A1 |
Disclosed are a PROTAC compound with cyclophilin A degradation activity, a preparation method therefor, and use thereof. The structural formula of the PROTAC compound is represented by formula (I). The compound represented by formula (I)...
|
|
WO/2024/032651A1 |
The present invention relates to the field of pharmaceutical synthesis. A long-acting insulin compound is disclosed. The long-acting insulin compound of the present invention for preparing a pharmaceutical composition for treating diseas...
|
|
WO/2024/036324A1 |
Provided herein are compositions and methods related to compositions comprising an Ig protease fusion protein. Also provided herein are compositions and methods for therapeutic treatment, such as of autoimmune diseases, allergies, or oth...
|
|
WO/2024/030886A1 |
The present disclosure provides, inter alia, methods for treating hemophilia A as well as computer-based-systems, including software-based pharmacokinetic model systems, and their use to determine dosing information for subjects who have...
|
|
WO/2024/029755A1 |
The present invention relates to an animal model of Charcot-Marie-Tooth disease caused by K141N or K141T mutations in HSPB8. In this animal model expressing the K141N or K141T mutant HSPB8 protein, symptoms of Charcot-Marie-Tooth disease...
|
|
WO/2024/031012A2 |
In some aspects, the present disclosure provides an implant. In some embodiments, the implant comprises a porous body comprising a form that fills a defect of a bone of a head of a subject. In some embodiments, the implant comprises a re...
|
